Pharmaceutical Technology25d
Adagrasib by Bristol-Myers Squibb for Metastatic Pancreatic Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have ...
Pharmaceutical Technology25d
Adagrasib by Bristol-Myers Squibb for Gynecological Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase I drugs for Gynecological Cancer have a 74% phase ...
Business Wire1mon
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development
including adagrasib (KRAS G12C selective inhibitor), MRTX1133 (KRAS G12D selective inhibitor) and MRTX1719 (MTA-cooperative PRMT5 inhibitor). Prior to Mirati, he served as head of Oncology ...